Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
CL Bennett, SM Silver, B Djulbegovic, AT Samaras… - Jama, 2008 - jamanetwork.com
Context The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin are
licensed to treat chemotherapy-associated anemia in patients with nonmyeloid …
licensed to treat chemotherapy-associated anemia in patients with nonmyeloid …
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
Abstract Purpose: To update the American Society of Clinical Oncology (ASCO)/American
Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents …
Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents …
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Background Erythropoiesis-stimulating agents reduce anaemia in patients with cancer and
could improve their quality of life, but these drugs might increase mortality. We therefore did …
could improve their quality of life, but these drugs might increase mortality. We therefore did …
Erythropoietin or darbepoetin for patients with cancer
T Tonia, A Mettler, N Robert… - Cochrane database …, 2012 - cochranelibrary.com
Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
Alternatives to blood transfusion
DR Spahn, LT Goodnough - The Lancet, 2013 - thelancet.com
The use of alternatives to allogeneic blood continues to rest on the principles that blood
transfusions have inherent risks, associated costs, and affect the blood inventory available …
transfusions have inherent risks, associated costs, and affect the blood inventory available …
Cancer-and chemotherapy-induced anemia
Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected
through either treating the underlying cause or providing supportive care through transfusion …
through either treating the underlying cause or providing supportive care through transfusion …
[BOOK][B] Berek and Hacker's gynecologic oncology
JS Berek, NF Hacker - 2010 - books.google.com
The focus of Berek and Hacker's for four editions has been on the application of basic and
clinical science to the clinical practice of gynecologic oncology. That approach has been …
clinical science to the clinical practice of gynecologic oncology. That approach has been …
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
J Glaspy, J Crawford, J Vansteenkiste, D Henry… - British journal of …, 2010 - nature.com
BACKGROUND: Cancer patients often develop the potentially debilitating condition of
anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents …
anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents …
Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable …
PG Rose, J Java, CW Whitney, FB Stehman… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To evaluate the prognostic factors in locally advanced cervical cancer limited to the
pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall …
pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall …
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with …
JD Rizzo, M Brouwers, P Hurley… - Blood, The Journal …, 2010 - ashpublications.org
Abstract Purpose: To update American Society of Hematology/American Society of Clinical
Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients …
Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients …